Literature DB >> 16126918

Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study.

David A Bluemke1, Dushyant Sahani, Marco Amendola, Thomas Balzer, Josy Breuer, Jeffrey J Brown, David D Casalino, Peter L Davis, Isaac R Francis, Glenn Krinsky, Fred T Lee, David Lu, Erik K Paulson, Lawrence H Schwartz, Evan S Siegelman, William C Small, Therese M Weber, Adam Welber, Kohkan Shamsi.   

Abstract

PURPOSE: To assess prospectively the efficacy and safety of postcontrast magnetic resonance (MR) imaging with gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) compared with that of precontrast MR imaging in patients who are known to have or are suspected of having liver lesions and who are scheduled for hepatic surgery.
MATERIALS AND METHODS: Investigational review board approval and written informed consent were obtained. HIPAA went into effect after data collection. A total of 172 patients were enrolled. After precontrast MR imaging, 169 patients (94 men, 75 women; mean age, 61 years; age range, 19-84 years) received an intravenous bolus of 25 micromol/kg Gd-EOB-DTPA and underwent dynamic gradient-recalled-echo and delayed MR imaging 20 minutes after injection. Arterial and portal phase computed tomography (CT) were performed within 6 weeks of MR imaging. The standard of reference was surgery with intraoperative ultrasonography (US) and biopsy and/or pathologic evaluation of resected liver segments and/or 3-month follow-up of nonresected segments if intraoperative US was not available. Three blinded reviewers and unblinded site investigators identified liver lesions on segment maps. The Wilcoxon signed rank test was used to compare differences in per-patient sensitivity of precontrast and postcontrast MR images. Adverse events were recorded, and patient monitoring and laboratory assay were performed at time of injection and up to 24 hours after contrast material administration.
RESULTS: At MR imaging, 316 lesions were identified in 131 patients. In 77% (P = .012), 72% (P = .15), and 71% (P = .027) of patients for readers 1, 2, and 3, respectively, more lesions were seen at precontrast and postcontrast MR imaging combined than at precontrast MR imaging alone. Sensitivity values for blinded readings were significantly greater at postcontrast MR imaging than at precontrast MR imaging for two of three blinded readers. For all blinded readers, combined precontrast and postcontrast MR images showed no difference in sensitivity compared with helical CT scans. The use of MR imaging, however, yielded fewer patients with at least one false-positive lesion (37%, 31%, and 34% of patients for readers 1, 2, and 3, respectively) than did helical CT (45%, 36%, and 43% of patients for readers 1, 2, and 3, respectively).
CONCLUSION: Compared with precontrast MR imaging, postcontrast MR imaging with Gd-EOB-DTPA demonstrated improved sensitivity for lesion detection in the majority of blinded readers, with no substantial adverse events. RSNA, 2005

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16126918     DOI: 10.1148/radiol.2371031842

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  65 in total

1.  Chronological evaluation of liver enhancement in patients with chronic liver disease at Gd-EOB-DTPA-enhanced 3-T MR imaging: does liver function correlate with enhancement?

Authors:  Shinichi Nakamura; Kazuo Awai; Daisuke Utsunomiya; Tomohiro Namimoto; Takeshi Nakaura; Kosuke Morita; Yasuyuki Yamashita
Journal:  Jpn J Radiol       Date:  2011-12-14       Impact factor: 2.374

Review 2.  CT and MR cholangiography: advantages and pitfalls in perioperative evaluation of biliary tree.

Authors:  T Hyodo; S Kumano; F Kushihata; M Okada; M Hirata; T Tsuda; Y Takada; T Mochizuki; T Murakami
Journal:  Br J Radiol       Date:  2012-03-14       Impact factor: 3.039

3.  High resolution navigated three-dimensional T₁-weighted hepatobiliary MRI using gadoxetic acid optimized for 1.5 Tesla.

Authors:  Scott K Nagle; Reed F Busse; Anja C Brau; Jean H Brittain; Alex Frydrychowicz; Yuji Iwadate; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2012-05-30       Impact factor: 4.813

4.  Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging.

Authors:  Katsutoshi Sugimoto; Fuminori Moriyasu; Junji Shiraishi; Kazuhiro Saito; Junichi Taira; Toru Saguchi; Yasuharu Imai
Journal:  Eur Radiol       Date:  2012-01-24       Impact factor: 5.315

5.  Effect of hepatobiliary uptake of Gd-EOB-DTPA on the hepatic venous phase of dynamic magnetic resonance imaging on a 3.0-T apparatus: comparison between Gd-EOB-DTPA and Gd-DTPA.

Authors:  Yasunari Fujinaga; Ayumi Ohya; Tsuyoshi Matsushita; Masahiro Kurozumi; Kazuhiko Ueda; Yoshihiro Kitou; Hitoshi Ueda; Masumi Kadoya
Journal:  Jpn J Radiol       Date:  2011-10-19       Impact factor: 2.374

6.  Optimized high-resolution contrast-enhanced hepatobiliary imaging at 3 tesla: a cross-over comparison of gadobenate dimeglumine and gadoxetic acid.

Authors:  Alex Frydrychowicz; Scott K Nagle; Sharon L D'Souza; Karl K Vigen; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2011-07-12       Impact factor: 4.813

7.  Health-economic evaluation of three imaging strategies in patients with suspected colorectal liver metastases: Gd-EOB-DTPA-enhanced MRI vs. extracellular contrast media-enhanced MRI and 3-phase MDCT in Germany, Italy and Sweden.

Authors:  C J Zech; L Grazioli; E Jonas; M Ekman; R Niebecker; S Gschwend; J Breuer; L Jönsson; S Kienbaum
Journal:  Eur Radiol       Date:  2009-06       Impact factor: 5.315

8.  Improved characterization of focal liver lesions with liver-specific gadoxetic acid disodium-enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial.

Authors:  Steven S Raman; Christopher Leary; David A Bluemke; Marco Amendola; Dushyant Sahani; Jeffrey D McTavish; Jeffrey Brody; Eric Outwater; Donald Mitchell; Douglas H Sheafor; Jeff Fidler; Isaac R Francis; Richard C Semelka; Kohkan Shamsi; Simone Gschwend; David R Feldman; Josy Breuer
Journal:  J Comput Assist Tomogr       Date:  2010 Mar-Apr       Impact factor: 1.826

Review 9.  Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions.

Authors:  Ahmed Ba-Ssalamah; Martin Uffmann; Sanjai Saini; Nina Bastati; Christian Herold; Wolfgang Schima
Journal:  Eur Radiol       Date:  2008-09-23       Impact factor: 5.315

10.  Characterization of the biliary tract by virtual ultrasonography constructed by gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging.

Authors:  Yohei Koizumi; Masashi Hirooka; Hironori Ochi; Yoshio Tokumoto; Megumi Takechi; Atsushi Hiraoka; Yoshio Ikeda; Teru Kumagi; Bunzo Matsuura; Masanori Abe; Yoichi Hiasa
Journal:  J Med Ultrason (2001)       Date:  2014-12-18       Impact factor: 1.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.